XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.20

-1.7%

1:12 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (10793)	7/14/1999 8:50:00 PM
From: Pseudo Biologist	Read Replies (1) of 17367

Thanks, it all makes sense. As the KPMG report makes clear, detection of LPS is always a problem. So, if BPI is blocking the LPS/LBP interaction with CD14, one would think that it's doing so by binding to LPS itself. But maybe this LPS can still be detected in their assay. In other words, can they distinguish free LPS from LPS bound to something (presumably BPI) that may neutralize it? Now, my understanding is that in this study detected LPS levels were similar in treated and untreated animals. Your last comment suggests that they were "similar low" as opposed to "similar high" so that in both groups LPS is being cleared. Of course, LBP, your proposed "clearing agent," is present (who knows at what levels? did they check? this would be a nice test of the LBP tests, wouldn't you say?) in both groups, treated and untreated. Am I reading this right? PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next